CTIX - Cellceutix Corporation (OTCBB)
I've been researching Cellceutix pretty heavily lately. Company is solid with a strong management team. Dr. Menon, who heads up the research team is nothing shy of brilliant. I will post more info on them as I learn it. Lower float play with most shares being held by insiders and the float being held relatively tightly by people that are optimistic about Cellceutix's future (according to CRO, Leo Ehrlich). A basic snapshot of Cellceutix:
Cellceutix Pharmaceuticals, Inc. (OTCBB: CTIX), located outside of Boston in Beverly, MA, is an emerging bio-pharmaceutical company in the business of developing small molecule therapies in areas of unmet medical need. Their primary efforts are in cancer and inflammatory disease, but also have another product in the pipeline that is being formulated to treat autism. Cellceutix flagship product, Kevetrin, is being developed to treat cancers that are resistant to standard treatments. Recently, Cellceutix has announced some exciting results in animal models of multi-drug resistant lung cancer.
Their business strategy is well-described by their company slogan “Compounds for Cures.” Cellceutix has kept a “low profile” as they have been developing their products with the ethical philosophy of their products alone will help patients and this will translate into rewards for shareholders. By biotechnology standards, their pipeline of products is moving forward rapidly through an experienced management and development team with years of experience in researching, developing and marketing pharmaceuticals. By “Over The Counter Bulletin Board” standards, their ethics are virtually unparalleled.
Press Release Source: Cellceutix On Monday March 29, 2010, 6:00 am
BEVERLY, MA--(Marketwire - 03/29/10) - Cellceutix Corporation (OTC.BB:CTIX - News), a bio-pharmaceutical company that develops small molecules to treat cancer and inflammatory disease, today announced positive results in an animal study of its recently acquired autism compound, KM-391. In this carefully conducted study, KM-391 was given orally over 90 days to groups of rats at two dosage levels. At each dosage level, KM-391 demonstrated significant improvements in the test animals when compared to both the "no treatment" group and the "active control" (fluoxetine) group on the parameters of brain plasticity, serotonin levels and behavioral function. These parameters were selected as important indicators of the effect needed to successfully treat autism.
More information about autism:
- 1% of the population of children in the U.S. ages 3-17 have an autism spectrum disorder. Prevalence is estimated at 1 in 110 births.
- More children will be diagnosed with autism this year than with AIDS, diabetes & cancer combined.
- 1 to 1.5 million Americans live with an autism spectrum disorder. 1% of the adult population of the United Kingdom have an autism spectrum disorder.
- Fastest-growing developmental disability; 10 - 17% annual growth.
- $60 billion estimated annual cost with 60% of costs in adult services. Cost of lifelong care can be reduced by 2/3 with early diagnosis and intervention.
- Autism receives less than 5% of the current U.S. private research funding, and less than 1% of the total NIH budget, even though it is the most prevalent childhood disorder.
The factors that may cause Cellceutix's actual results to differ from its forward-looking statements include: Cellceutix's current critical need for additional cash to sustain existing operations and meet ongoing existing obligations and capital requirements; Cellceutix's ability to implement its new product development and commercialization, enter into clinical trials, expand the intellectual property portfolio, and receive regulatory approvals in a timely and cost-effective manner. All forward-looking statements are also expressly qualified in their entirety by the cautionary statements included in Cellceutix's SEC filings, including its quarterly reports on Form 10-Q and its annual report on Form 10-K.
The heights by great men reached and kept, were not obtained by sudden flight. But they, while their companions slept, were toiling upward in the night." - Longfellow
"If the life you have created
Is founded on jealousy and hatred...
It's too late to ask questions
For you're much too old to take any suggestions"